Journal of Animal Reproduction and Biotechnology (한국동물생명공학회지)

The Korean Society of Animal Reproduction and Biotechnology (한국동물생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Cisplatin and lipopolysaccharide co-administration for renal injury model in mice

  • Sae-Byeok Hwang (Cell Therapy 3 Center, CHA Advanced Research Institute, CHA Bundang Medical Center) ;
  • Soon-Suk Kang (Cell Therapy 3 Center, CHA Advanced Research Institute, CHA Bundang Medical Center) ;
  • Yeonmi Lee (Cell Therapy 3 Center, CHA Advanced Research Institute, CHA Bundang Medical Center) ;
  • Eunju Kang (Cell Therapy 3 Center, CHA Advanced Research Institute, CHA Bundang Medical Center)
  • Received : 2024.10.12
  • Accepted : 2024.11.19
  • Published : 2024.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Cisplatin, a chemotherapeutic agent often causes nephrotoxic side effects. Lipopolysaccharide (LPS) is known to induce pro-inflammatory responses, often leading to septic renal injury. We hypothesized that the combination of cisplatin and LPS would amplify renal injury, thereby improving a renal injury model. Therefore, we administered both agents to mice and evaluated renal injury indicators. Methods: Eight-week-old male C57BL/6 mice were injected with cisplatin (8, 10, or 12 mg/kg) and LPS (5 mg/kg) on days 1 and 4 following of each week. Mice were euthanized at specific time points to assess renal injury. Body weight, renal weight, area, and BUN levels were measured to evaluate renal damage. Additionally, hematoxylin and eosin (H&E) and Masson's trichrome (MT) staining were performed to assess histological changes. Results: The combination of cisplatin and LPS significantly reduced body and renal weight compared to cisplatin alone. A high dose of cisplatin (12 mg/kg) resulted in a 50% mortality, while, lower doses (8 and 10 mg/kg) showed 100% survival. Significant renal injury was observed in the 10 mg/kg cisplatin group administered for two weeks. In the 8 mg/kg cisplatin group, no changes were observed after two weeks, but renal damage appeared after four weeks. Histological evaluations in the 10 mg/kg cisplatin group administered for two weeks showed renal injury features, including tubular damage and fibrosis. Conclusions: Administering cisplatin (10 mg/kg) with LPS for two weeks or cisplatin (8 mg/kg) with LPS for four weeks resulted in a distinct renal injury, effectively establishing a renal injury mouse model.

Keywords

Acknowledgement

This work was supported by an intramural research program from the CHA Advanced Research Institute, grant number CARI-RD-017. This research was supported by a grant of Korean Cell-Based Artificial Blood Project funded by the Korean government (The Ministry of Science and ICT, The Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (grant number: RS-2023-KH140925).

References

  1. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, El-lis P, Guzman J. Marshall J, Parrillo JE, Skrobik Y, Kumar A. 2009. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 35: 871-881. https://doi.org/10.1007/s00134-008-1367-2
  2. Berru FN, Gray SE, Thome T. Kumar RA, Salyers ZR, Coleman M, Dennis Le, O'Malley K, Ferreira LF, Berceli SA, Scali ST, Ryan TE. 2019. Chronic kidney disease exacerbates ischemic limb myopathy in mice via altered mitochondrial energetics. Sci. Rep. 9: 15547. https://doi.org/10.1038/s41598-019-52107-7
  3. Curry JN and McCormick JA. 2022. Cisplatin-induced kidney injury: delivering the goods. J. Am. Soc. Nephrol. 33:255-256. https://doi.org/10.1681/ASN.2021121591
  4. Elbrolosy MA, Helal MG, Makled MN. 2024. CGS-21680 defers cisplatin-induced AKI-CKD transition in C57/BL6 mice. Chem. Biol. Interact. 403: 111255. https://doi.org/10.1016/j.cbi.2024.111255
  5. Fu Y, Xiang Y, Wu W, Cai J, Tang C, Dong Z. 2024. Corrigendum: persistent activation of autophagy after cisplatin nephro-toxicity promotes renal fibrosis and chronic kidney disease. Front. Pharmacol. 15: 1387592. https://doi.org/10.3389/fphar.2024.1387592
  6. Grillo-Marin C, Anton-Rodriguez C, Prieto L, Ortega-Perez G, Gonzalez-Moreno S. 2024. Nephrotoxicity associated with cytoreductive surgery combined with cisplatin-based hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease: a systematic review and meta-analysis. J. Clin. Med. 13: 3793. https://doi.org/10.3390/jcm13133793
  7. Li Y, Luo C, Cai Y, Wu Y, Shu T, Wei J. Wang H, Niu H. 2024. IGF2BP3/NCBPI complex inhibits renal tubular senescence through regulation of CDK6 mRNA stability. Transl. Res. 273: 1-15. https://doi.org/10.1016/j.trsl.2024.06.004
  8. Manohar S and Leung N. 2018. Cisplatin nephrotoxicity: a re-view of the literature. J. Nephrol. 31:15-25. https://doi.org/10.1007/s40620-017-0392-z
  9. Santos DD, Belote NM, Sasso GRS, Correia-Silva RD, Franco PC, da Silva Neto AF, Borges FT, Oyama LM, Gil CD. 2024. Effect of modified citrus pectin on galectin-3 inhibition in cisplatin-induced cardiac and renal toxicity. Toxicology 504: 153786. https://doi.org/10.1016/j.tox.2024.153786
  10. Sanz AB, Sanchez-Nino MD, Ramos AM, Ortiz A. 2023. Regulat-ed cell death pathways in kidney disease. Nat. Rev. Nephrol. 19: 281-299. https://doi.org/10.1038/s41581-023-00694-0
  11. Tang C, Livingston MJ, Safirstein R, Dong Z. 2023. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat. Rev. Nephrol. 19: 53-72. https://doi.org/10.1038/s41581-022-00631-7
  12. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, Arsenijevic N. 2019. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci. 26: 25. https://doi.org/10.1186/s12929-019-0518-9
  13. Xiu GH, Zhou X, Li XL, Chen XZ, Li BQ, Chen XL, Jin H, Pan XH, Sun J. Ling B. 2018. Role of bone marrow mesenchymal stromal cells in attenuating inflammatory reaction in lipopolysaccaride-induced acute kidney injury of rats asso-ciated with TLR4-NF-KB signaling pathway inhibition. Ann. Clin. Lab. Sci. 48: 743-750.
  14. Yang S, Ye Z, Chen W, Wang P, Zhao S, Zhou X, Li W, Cheng R. 2024. BMALI alleviates sepsis-induced AKI by inhibiting ferroptosis. Int. Immunopharmacol. 142(Pt B): 113159. https://doi.org/10.1016/j.intimp.2024.113159
  15. Zheng D, Ruan X, Wu Q, Qiu Y, Ruan S. 2024. Yishen Jiangzhuo decoction attenuates cisplatin-induced acute kidney injury by inhibiting inflammation, oxidative stress and apoptosis through the TNF signal pathway. Exp. Ther. Med. 28: 331.